Skip to main content
峆一药业 logo

峆一药业 — Investor Relations & Filings

Ticker · 920478 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 363 across all filing types
Latest filing 2024-04-10 Board/Management Inform…
Country CN China
Listing Beijing Stock Exchange 920478

About 峆一药业

http://www.heryipharma.com/

Anhui Heyi Pharmaceutical Co., Ltd. specializes in the research, development, production, and sales of pharmaceutical intermediates and active pharmaceutical ingredients (APIs). The company focuses on providing high-quality chemical products for various therapeutic areas, including cardiovascular, central nervous system, and anti-infective treatments. With a strong emphasis on technological innovation and quality control, it operates advanced manufacturing facilities that adhere to international standards. Its product portfolio includes key intermediates for widely used medications, supporting both domestic and global pharmaceutical supply chains. The company leverages its expertise in complex chemical synthesis to offer customized solutions and reliable supply to its partners in the life sciences sector.

Recent filings

Filing Released Lang Actions
2023 年度独立董事述职报告（杨模荣）
Board/Management Information Classification · 95% confidence The document is a detailed report by an independent director of Anhui Xiyi Pharmaceutical Co., Ltd. on their duties and activities during the 2023 fiscal year. It includes attendance records at board and shareholder meetings, opinions on various board resolutions, supervision of internal audits and financial reporting, and compliance with governance and regulatory requirements. The content focuses on the independent director's oversight and governance role rather than financial results or audit opinions alone. The document length is about 3100 characters, which is relatively short but contains substantive content about board and management oversight rather than just an announcement or certification. It is not a full annual report, audit report, or earnings release, nor is it a simple announcement or certification. The document fits best into the category of Board/Management Information (MANG), as it reports on the activities and supervision by a board member (independent director) during the year.
2024-04-10 Chinese
关于使用自有资金进行现金管理的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from Anhui Xuyi Pharmaceutical Co., Ltd. regarding the use of its own funds for cash management through investment in short-term, high-liquidity, and safe financial products. It details the purpose, amount, method, duration, decision-making process, risk analysis, and impact on the company. The document includes resolutions from the board and supervisory meetings and is dated April 11, 2024. The content is about a financing activity related to the company's capital management and investment of own funds, not a financial report or earnings release. It is not a report publication announcement or regulatory filing. Therefore, the document fits best under Capital/Financing Update (CAP). The document length is short (1345 characters), but it contains substantive information about financing activities, not just a notice or certification.
2024-04-10 Chinese
2023年度募集资金存放与实际使用情况的专项报告
Capital/Financing Update Classification · 95% confidence The document is titled as a "2023 Annual Special Report on the Deposit and Actual Use of Raised Funds" by Anhui Xuyi Pharmaceutical Co., Ltd. It details the company's fundraising activities, including the issuance of new shares, the amount of funds raised, their management, and actual usage during the 2023 fiscal year. It includes specific financial figures related to fundraising, usage status, and compliance with regulatory requirements. The document also contains auditor and sponsor institution opinions verifying the proper use and management of the raised funds. The content focuses on the management and use of capital raised through equity issuance, which aligns with a Capital/Financing Update rather than a full Annual Report or other categories. The document length is 4322 characters, which is substantial and contains detailed financial data, so it is not a mere announcement or certification. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2024-04-10 Chinese
第四届董事会第十五次会议决议
Board/Management Information Classification · 95% confidence The document is a detailed announcement of resolutions passed at the 15th meeting of the 4th Board of Directors of Anhui Xuyi Pharmaceutical Co., Ltd. It includes information about meeting attendance, agenda items, voting results, and references to various reports and announcements published elsewhere (e.g., annual report, audit report, independent director reports) on the Beijing Stock Exchange website. The document itself does not contain the full annual report or audit report but rather the board's resolutions approving these reports and plans to submit them to the shareholders' meeting. This type of document is a formal board meeting resolution announcement, which falls under Board/Management Information (MANG) as it relates to board decisions and management reports. It is not the full Annual Report (10-K) or Audit Report (AR) itself, nor is it a simple announcement of report publication (RPA). Therefore, the correct classification is MANG with high confidence.
2024-04-10 Chinese
使用部分闲置募集资金购买理财产品公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from Anhui Xuyi Pharmaceutical Co., Ltd. regarding the use of part of its idle raised funds to purchase financial products. It details the amount of funds raised, their current usage status, the decision-making process by the board and supervisory committee, risk control measures, and opinions from the supervisory board and sponsoring institution. The document is relatively short (2819 characters) and focuses on the usage of raised capital rather than presenting financial statements or comprehensive financial data. It is not a full financial report but an update on capital usage and compliance with regulatory requirements. This fits the definition of a Capital/Financing Update (CAP) rather than an Annual Report, Interim Report, or Regulatory Filing. Therefore, the appropriate classification is CAP with high confidence.
2024-04-10 Chinese
董事会审计委员会2023年度履职情况报告
Audit Report / Information Classification · 95% confidence The document is a detailed report from the Audit Committee of the Board of Directors of Anhui Xiyi Pharmaceutical Co., Ltd. It discusses the committee's activities during the 2023 fiscal year, including reviewing financial reports, supervising external auditors, and ensuring compliance with relevant regulations. The document includes specific references to the audit committee's meetings, their review of quarterly and annual reports, and their oversight of the external audit process. It does not contain the full financial statements or the complete annual report itself but rather focuses on the audit committee's work and opinions related to the audit and financial reporting process. This aligns with the definition of an Audit Report / Information (AR), which includes standalone audit reports and results of internal or regulatory audits, excluding the full Annual Report (10-K). The document length is 1883 characters, which is relatively short but contains substantive content about audit activities rather than just an announcement or certification. Therefore, the appropriate classification is AR with high confidence. FY 2023
2024-04-10 Chinese

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.